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Aim: This study aims to investigate the role of CO2 laser evaporation in the treatment of melanoma pa-
tients with satellite or in-transit metastases. Materials & methods: Patients who underwent CO2 laser
evaporation were retrospectively included between November 2002 and August 2018. The Sharplan 40C
CO2 laser was used with a high pulse wave mode. Data concerning patient and tumor characteristics, CO2
laser evaporation and subsequent therapies were collected. Results: A total of 26 patients were included.
Median duration of local control was 5.5months. Themedian number of lesions evaporated per treatment
was three (1–16); patients received a median of three (1–19) treatments. Conclusion: In a selected group
of melanoma patients with satellite or in-transit metastases, CO2 laser evaporation should be considered
as treatment for local control.
First draft submitted: 2 November 2018; Accepted for publication: 18 February 2019; Published online:
18 April 2019
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The incidence rate of cutaneous melanoma is still increasing worldwide, in the USA, an estimate of 91,270 patients
will be diagnosed with melanoma in 2018 and approximately 9320 will die from the disease in the same year [1].
When the disease is detected in an early stage and confined to its primary location, cure rates are high [2]. However,
metastases are frequently seen.
Locoregional metastases such as cutaneous or subcutaneous metastases are thought to be caused by lymphatic
dissemination. Melanoma cells are trapped within the lymphatic vessels and spread between the primary melanoma
site and the draining regional lymph nodes [3–5]. Locoregional metastases are historically classified into satellite
metastases (<2 cm of the primary tumor) and in-transit metastases (≥2 cm of the primary tumor). Despite this
distinction, in clinical practice they are not considered as different entities for treatment or prognosis [2,6].
A substantial number of patients (4–10%) develop satellite or in-transit metastases approximately 16–18 months
after local initial excision of the primary tumor [3–5]. Risk factors for the development of satellite or in-transit
metastases are Breslow thickness, ulceration, a primary tumor on the lower extremity and a positive sentinel lymph
node biopsy [4,5]. Diagnosis is usually clinical since the (sub)cutaneous metastases are often palpable or visible in the
skin, thus easy to recognize [7]. Due to ulceration, bleeding, infection and pain, satellite and in-transit metastases
can have a significant impact on the patients’ quality of life.
The treatment of satellite or in-transit metastases is a challenge, mainly due to the great variation in clini-
cal presentation and the unpredictable behavior of the disease. The appearance can range from very few small
(sub)cutaneous lesions to large numbers of bulky lesions distributed over an extremity, the head and neck region or
trunk.When satellite or in-transit metastases are limited, surgical resection is the preferred treatment [7–9]. However,
in some cases, this is not feasible. In patients with satellite or in-transit metastases located in the head and neck
region, a surgical resection can be severely mutilating. Furthermore, in patients with extensive disease distributed
over an extremity, surgical resection can be technically challenging, too invasive or might even be impossible.
Hyperthermic isolated limb perfusion (HILP) and isolated limb infusion (ILI) are alternative treatment options.
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However, both procedures are associated with morbidity and regional toxicity and are therefore not always suitable
in patients with multiple comorbidities.
Locoregional metastases are present in Stage III as well as Stage IV disease. In recent years, several novel and
successful systemic treatments have been developed with improvement of survival; however, locoregional control
cannot always be achieved [10–12]. Growing evidence suggests that concurrent systemic and locoregional therapy
enhances efficacy [13,14].
CO2 laser evaporation is a simple and effective treatment option for satellite or in-transit metastases that can be
performed under local or regional anesthesia and can be repeated if new lesions develop [15–18]. Previous research has
shown that in selected patients, adequate local control can be achieved with low morbidity rates [18]. The CO2 laser
evaporation might be an attractive treatment alternative in the above-mentioned situations. In this study, we aimed
to investigate the role of CO2 laser evaporation in the treatment of patients with satellite or in-transit metastases,
in the era of effective systemic therapy.
Materials & methods
Study design & population
A retrospective study was conducted at the Department of Surgical Oncology of the University Medical Center
Groningen (UMCG). The UMCG is a university hospital and tertiary referral center in the northern part of the
Netherlands. Melanoma patients with satellite or in-transit metastases, who underwent CO2 laser evaporation
between November 2002 and August 2018, were included in the database. Patients with both American Joint
Committee on Cancer Stage III and IV disease were included.
Baseline demographic information was obtained from digital files stored in the electronic database of the hospital
including patients’ age, gender, medical history, American Society of Anesthesiologists score and primary melanoma
characteristics.
Most patients underwent initial treatment of the primary melanoma in hospitals elsewhere and were referred to
the UMCG for further treatment. Patients received various combinations of treatment modalities before and/or
after laser therapy. Data concerning the duration of each therapy as well as the indication to change therapy were
collected. The duration of therapy was defined as the time from the start of a therapy until the start of a subsequent
therapy or death of the patient.
Data concerning the CO2 laser evaporation were retrieved retrospectively and included the number of laser treat-
ments, the number of lesions treated per session, the location of satellite or in-transit metastases and complications.
CO2 laser evaporation
Lesions with a diameter ≤10 mm were deemed eligible for treatment with CO2 laser evaporation (Figure 1). All
patients were treated under local anesthesia at an outpatient clinic by the same expert physician. The Sharplan
40C CO2 laser was used, with a handpiece or a micromanipulator together with an operation microscope (Zeiss
Opmi 1). The treatment was carried out by moving a slightly defocused CO2 laser spot over the lesion. The spot
size was adjusted to the size of the lesion and differed from 0.5–4 mm. Multiple pulses were given until the lesion
was completely evaporated. A high pulse wave mode with an output power of 5–10 W was used. The operation
microscope with a connected scanning device was especially useful in the head and neck area, achieving a more
accurate treatment with minimal collateral damage. The laser beam was used in focus, and the size of the treated
area could be programmed from 1–6 mm. By using the laser in focus, there was less carbonization and the results
could therefore be better assessed. Postoperatively, the wounds were dressed with Vaseline gauze for 7–14 days. Each
lesion was completely evaporated during one CO2 laser sessions. However, in case of numerous lesions, more CO2
laser sessions were required. The interval of treatment sessions depended on the number of lesions and recurrence.
In some patients, one session was enough, whereas other patients were seen every month.
Statistical analyses
IBM SPSS Statistics, version 22, was used for descriptive statistics. Continuous variables were described as mean
with standard deviation or median with interquartile range, and categorical variables as count (n) with percentage
(%).
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Figure 1. Melanoma patient with in-transit metastases eligible
for CO2 laser therapy.
Ethical approval
The Medical Ethical Committee granted dispensation according to the Dutch law regarding patient based medical
research obligation (METc registration no. 2017003). The data were retrospectively collected in an electronic
database and processed according to the Declaration of Helsinki [19].
Results
Patient & melanoma characteristics
A total of 26 patients (female n = 15; male n = 11) were treated with CO2 laser evaporation for satellite or
in-transit metastases between November 2002 and August 2018. Baseline patient and melanoma characteristics
are summarized in Table 1. The median age at initial treatment for satellite or in-transit metastases was 71 year
(range = 42–88). The primary melanoma was located on the lower extremity in 77% of patients, the head and neck
in 15% of patients, and trunk in 8% of patients. Median overall Breslow thickness of the primary melanoma was
3.3 mm (range = 1.5–8.0). In one patient the Breslow thickness was >1 mm; however, the exact Breslow thickness
was unknown. Superficial spreading melanoma was the most common histological subtype (58%).
CO2 laser evaporation
The CO2 laser evaporation was performed for satellite or in-transit metastases located on the lower extremity in
20 patients (77%), head and neck in five patients (19%) and trunk in one patient (4%). The median number of
lesions treated during one CO2 laser evaporation session was 3 (range = 1 to 16). There were two complications,
including delayed wound healing and the development of an ulcer in a patient with chronic venous insufficiency.
For almost all lesions, one treatment was enough to evaporate the lesion. Multiple treatment sessions were indicated
due to the development of new lesions in the same region, with a median number of three treatment sessions per
patient. The median duration of local control with CO2 laser evaporation was 5.5 months (range = 0.5 to 63;
Table 2). Reasons for termination of CO2 laser evaporation were local progression in 17 patients (65%), distant
metastases in eight patients (31%) and lymph node metastases in two patients (7%). Local progression included
progression in number (>15) or size (>10 mm), or the development of subcutaneous lesions. In one patient, CO2
laser evaporation is currently still performed. The median time of survival after initial treatment of the satellite or
in-transit metastases was 45 months (Table 2).
Follow-up
The timelines for all individual patients, from the start of CO2 laser evaporation for satellite or in-transit metastases,
are presented in a swimmers plot (Figure 2). Each colored bar represents the duration of a therapy, from start of one
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Table 1. Baseline patient and tumor characteristics.
Characteristics Number (%) and median (range)
Gender
– Male 11 (42.3)
– Female 15 (57.7)
Age, years† 71 (42–88)
Location of primary lesion
– Lower extremity 20 (76.9)
– Upper extremity 0 (0.0)
– Head and neck 4 (15.4)
– Trunk 2 (7.7)
Histologic typing
– Superficial spreading 15 (57.7)
– Nodular 7 (26.9)
– Nevoid 1 (3.8)
– Acral lentiginous 1 (3.8)
– Unable to classify 1 (3.8)
– Unknown primary 1 (3.8)
Breslow thickness, mm 3.3 (1.5–8.0)
T stage
– T1 (1.00 mm) 0 (0.0)
– T2 (1.01–2.00 mm) 7 (26.9)
– T3 (2.01–4.00 mm) 11 (42.3)
– T4 (4.00 mm) 6 (23.1)
– Unknown primary 1 (3.8)
– Unknown 1 (3.8)
Ulceration
– Yes 7 (26.9)
– No 18 (69.2)
– Unknown primary 1 (3.8)
AJCC stage
– IIIB 12 (46.2)
– IIIC 13 (50.0)
– IV 1 (3.8)
†Age at initial treatment satellite/in-transit metastases.
AJCC: American Joint Committee on Cancer.
therapy until the start of a subsequent therapy. The median duration of CO2 laser evaporation was 5.5 months.
In six patients (24%) CO2 laser evaporation was combined with another treatment, including systemic treatment
in three patients, local treatment in two patients and palliative care in one patient. After CO2 laser evaporation,
21 (81%) patients received an additional treatment modality during follow-up, including radiotherapy (33%),
systemic treatment (19%) or additional surgical interventions, including local treatment (24%), HILP or ILI
(19%), or a lymph node dissection (5%) due to locoregional progression of disease. At the end of follow-up, six of
the 26 patients were alive.
Discussion
This retrospective study shows that CO2 laser evaporation is an attractive treatment option for a selected group
of melanoma patients with satellite or in-transit metastases. The CO2 laser evaporation has shown to be efficient
and effective, and can be performed under local anesthesia in an outpatient clinic setting with low morbidity
and complication rates. Even in the era of effective systemic treatment, CO2 laser evaporation is a good palliative
treatment option, aiming to stabilize disease and maintain quality of life. Based on the results of this study, we
propose a treatment algorithm which will be discussed below (Figure 3).
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Table 2. Details of CO2 laser evaporation.
Characteristics Number (%) and median (range)
Location satellite/in-transit metastases
– Lower extremity 20 (76.9)
– Upper extremity 0 (0.0)
– Head and neck 5 (19.2)
– Trunk 1 (3.8)
Number of laser treatments 3 (1–19)
Number of lesions per session 3 (1–16)
Complications
– Yes 2 (7.7)
– No 24 (92.3)
Reason for termination of therapy
– Local progression† 17 (65.4)
– Lymph node metastases 2 (6.9)
– Distant metastases 8 (30.8)
– Complications 0 (0.0)
– Unknown 2 (6.9)
Duration of local control, months 5.5 (0.5–63.0)
Survival, months‡ 45.0 (5.0–124.0)
†Local progression included progression in number (15) or size ( 10 mm), or the development of subcutaneous lesions.
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Figure 2. Swimmers plot of the course of disease and treatment history of all individual patients with satellite or in-transit metastases.
At the time of diagnosis of satellite or in-transit metastases, the risk of occult nodal or distant metastases
is substantial; therefore, all patients should be carefully staged. The diagnostic tool of preference in stage III
melanoma patients for the detection of metastases is a fluorine-18 labeled fluorodeoxyglucose positron emission
tomography (18F-FDG PET) [20]. Combined with a diagnostic CT scan, it can reach a sensitivity of 86% and
specificity of 91% for the detection of melanoma metastases [21]. Based on the stage of the disease, a patient-tailored
treatment plan can be made.
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Figure 3. Treatment flow-chart for patients with satellite or in-transit metastases.
CT: Computed tomography; FDG-PET: Fludeoxyglucose-positron emission tomography; HILP: Hyperthermic isolation limb perfusion; ILI:
Isolated limb perfusion.
For patients with satellite or in-transit metastases without distant disease, surgical excision is the treatment of
choice, if technically feasible [7–9]. When the satellite or in-transit metastases are not amenable to surgical resection,
either HILP or ILI is suggested if the disease is limited to an extremity. However, both procedures are invasive,
require general anesthesia, hospital admission for at least several days, and may be associated with morbidity and
regional toxicity [22]. In addition, HILP is not appropriate in patients with multiple comorbidities. In this study,
HILP or ILI was not feasible in three patients (patient 15, 20 and 25) and CO2 laser evaporation was performed
without complications. Locoregional control was achieved during respectively 10, 8 and 4 months after which
treatment was changed to another modality due to progression of disease.
Surgery can be mutilating in recurrent disease, especially when satellite or in-transit metastases are located in
the head and neck region. Topical and intralesional therapies are alternative treatment modalities in these patients
in addition to CO2 laser evaporation. Imiquimod 5% cream (Aldara R©) and topical diphencyprone are approved
for the treatment of warts, solar keratosis, superficial basal cell carcinoma and alopecia areata but have also been
reported for the treatment ofmelanomametastases [23–27]. Both are inexpensive, simple to apply and easily accessible;
however, the effect is limited to superficial lesions. Imiquimod has been combined with intralesional IL-2 in the
treatment of subcutaneous lesions [23,24,28,29]. Regression of lesions has been reported in up to 50% of patients for
Imiquimod and 84% for diphencyprone [7,23,27]. Side effects are usually mild and include flu-like symptoms and
local reaction such as erythema and erosions, but severe blistering has been seen in some cases [24,25].
Talimogene Laherarepvec (T-VEC) is an oncolytic immunotherapy, derived from herpes simpex virus type I and
is approved for the treatment of stage IIIB, IIIC and IVM1a disease [30,31]. It causes death of tumor cells and initiates
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an antitumor immune response after administration via intralesional injection [7]. An overall response rate of 26.4%
has been seen with mild adverse events including fatigue, chills and pyrexia [32]. However, T-VEC is costly and
there are several important management considerations [30]. Another intralesional therapy is electrochemotherapy
(ECT), which consist of injection of a chemotherapeutic drugs followed by application of electrical pulses to the
tumor [33–35]. A systematic review by Aguado-Romeo et al. [33] showed that ECT appears to be an effective procedure
for the local treatment of satellite or in-transit melanoma metastases; however, the level of evidence is low. Besides
topical and inralesional therapies, radiotherapy is used in the treatment of metastatic melanoma. However, there is
a limited role for radiotherapy as first-line management of satellite or in-transit metastases [8]. Especially wide-field
radiation is not indicated in the view of considerable morbidity [29].
Ablation of satellite or in-transit metastases can be performed using laser or electrocautery [36]. Electrocautery
is a simple technique used in several clinics with a small scientific basis in melanoma patients. Furthermore, we
believe that electrocautery may cause more collateral damage compared with CO2 laser. Previous studies have
shown that CO2 laser evaporation can be used for cutaneous and superficial subcutaneous melanoma metastases
with a maximum diameter of 5–20 mm [15–18]. In our study, lesions ≤10 mm were deemed eligible for CO2 laser
evaporation. In larger lesions, more infiltration is usually present and a significant defect is created without the
certainty that the lesion is completely evaporated, especially in the deeper skin layers, with the risk of local recurrence,
infection and wound problems. The number of lesions treated during one CO2 laser evaporation session in our
study (median = 3; range = 1–16) was less than in previous studies (median = 6–20; range = 1–450) [16,18,37,38]. The
CO2 laser evaporation was performed under local anesthesia in our study, whereas in other studies the procedure
was performed under local or regional anesthesia depending on the amount and location of the lesions. The use
of local anesthesia limits the number of lesions that can be treated during one procedure; however, the advantage
is that the procedure will only take 10–15 min. For a superficial large area with satellite or in-transit metastases
or confluent lesions, CO2 laser evaporation is not appropriate and a topical therapy might be a better treatment
modality. However, for small (≤10 mm), numerous (0–15) lesions CO2 laser evaporation is more suitable.
Growing evidence suggests that concurrent systemic and locoregional treatment synergizes antitumor effects
in patients with stage IV disease. Locoregional treatment of metastases is thought to cause an immune mediated
phenomenon resulting in the regression of tumors outside the scope of the localized treatment. This so-called
abscopal effect is reported in melanoma patients treated with radiotherapy and in patients treated with CO2 laser
evaporation with remission of untreated deposits [39–41]. Previous studies have shown promising results combining
immune checkpoint blockade (ipilimumab) with either radiotherapy, ECT, T-VEC or imiquimod [14,42–44]. In our
study, in three patients (patient 9, 12 and 26) systemic treatment was combined with CO2 laser evaporation. One
of these patients developed in-transit metastases located at the lower eyelid and cheeks during systemic treatment
causing symptoms, which were successfully treated with CO2 laser evaporation. Combined CO2 laser evaporation
and systemic therapy might synergize the immunotherapeutic effects.
There are several limitations of this study that need to be addressed. First of all, the retrospective nature of
this study; not all tumor factors (e.g., lesion size) were available for analyses, furthermore, as in most retrospective
studies there are somemissing data. The CO2 laser therapy was combined with systemic treatment in some patients,
making assessment of the value of CO2 laser therapy difficult. However, this was the case in only three patients.
Conclusion
There are several treatment modalities that can be used for the treatment of satellite or in-transit melanoma metas-
tases, including CO2 laser evaporation. The Al treatment modalities have their own advantages and disadvantages as
described above. The CO2 laser evaporation results in rapid removal of lesions. There is minimal collateral damage
of surrounding tissue, easily managed wound care, minimal complications and good cosmetic results. In a selected
group of melanoma patients with satellite or in-transit metastases, CO2 laser evaporation should be considered as
treatment for local control when surgical resection is not amenable.
Future perspective
Developments in systemic therapy, including immunotherapy, are currently changing the standard of care of
melanoma patients. Not only in recent years, but also in the future, systemic therapy will play a more important
role in the treatment of melanoma patients. Despite this, there will remain a group of patients who will benefit
from simple, local therapy with good cosmetic outcome and few complications, aiming for a good quality of life.
Since the long-term results of systemic therapy are still unknown, future research should be aimed at determining
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whether the combination of systemic therapy and local therapy (e.g., CO2 laser evaporation) improves not only
locoregional control but also survival.
Summary points
• A substantial number of melanoma patients develop satellite or in-transit metastases, which can have a
significant impact on the patients’ quality of live due to ulceration, bleeding, infection and pain.
• Treatment of satellite and in-transit metastases can be a challenge due to the variation in clinical presentation
and the unpredictable behavior of the disease. Surgical resection is, if possible, the preferred treatment.
• In extensive disease, metastases located at the head and neck region or in patients with multiple comorbidities,
surgical resection might be mutilating, too invasive or even be impossible and alternative treatment options
should be used.
• There are various modalities for the treatment of melanoma satellite or in-transit metastases including topical
therapies (e.g., Imiquimod, topical diphencyprone), intralesional therapies (e.g., talimogene laherarepvec
[T-VEC], elecrochemotherapy), radiotherapy and CO2 laser evaporation.
• The CO2 laser evaporation results in rapid removal of lesions with minimal collateral damage of surrounding
tissue, easily managed wound care and minimal complications, and should be considered as treatment for local
control in a selected group of melanoma patients with satellite or in-transit metastases.
• It is to be determined whether combined systemic and local therapy by means of CO2 laser evaporation improves
not only locoregional control but also survival.
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